Literature DB >> 29018296

Pharmaceutical Approval Update.

Michele B Kaufman.   

Abstract

L-glutamine oral powder (Endari) for reducing the acute complications of sickle cell disease; edaravone (Radicava) for the treatment of amyotrophic lateral sclerosis; and midostaurin (Rydapt) for the treatment of acute myeloid leukemia in combination with chemotherapy.

Entities:  

Year:  2017        PMID： 29018296      PMCID： PMC5614411     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

1.  Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice.

Authors:  Nadine Keleku-Lukwete; Mikiko Suzuki; Harit Panda; Akihito Otsuki; Fumiki Katsuoka; Ritsumi Saito; Daisuke Saigusa; Akira Uruno; Masayuki Yamamoto
Journal:  Blood Adv       Date:  2019-04-23

Review 2.  Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.

Authors:  Piyusha P Pagare; Aref Rastegar; Osheiza Abdulmalik; Abdelsattar M Omar; Yan Zhang; Andrew Fleischman; Martin K Safo
Journal:  Expert Opin Ther Pat       Date:  2021-11-01       Impact factor: 6.714
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.